Kexing Biopharm Co.,ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Kexing Biopharmaceutical Co., Ltd. is an innovative biopharmaceutical enterprise mainly engaged in the research and development, production, and sales integration of recombinant protein drugs and microecological preparations. It focuses on the treatment fields of antiviral, tumor and immunity, blood, digestion, degenerative diseases, etc. It builds cutting-edge biotechnology platforms for new proteins, new antibodies, nucleic acid drugs, and adheres to the "innovation+internationalization" dual wheel driven platform development model, At the same time, we will explore the widespread application of biotechnology in the field of big health, actively cultivate and incubate new industries, and strive to become a leader in high-quality biopharmaceuticals, serving patients worldwide. The main products include recombinant protein drugs such as "human erythropoietin" and "human interferon α 1b (Serokin) "," Human Granulocyte Stimulating Factor (Bai Texi) "microecological preparation drug" Clostridium butyricum bifunctional live bacteria (Changlekang) ", the exclusive traditional Chinese patent medicines and simple preparations" Kehuang capsule ", the chemical drug" Entecavir ", as well as the introduction of high-end complex preparation" white egg paclitaxel ", the monoclonal antibody drugs" infliximab (Riten) "," bevacizumab "and" Adalimumab ". In recent years, Kexing Pharmaceutical's business has continued to grow rapidly and has become a leading enterprise in recombinant protein drugs. The core product ranks among the top of similar varieties in China, covering nearly 20000 terminals in various provinces and cities across the country, including nearly 7000 grade hospitals. It has achieved market access and sales in nearly 40 countries and regions around the world, such as Brazil, the Philippines, and Indonesia. After more than 20 years of pharmaceutical research and industrialization technology accumulation, Kexing Pharmaceutical has built a complete pharmaceutical research and development innovation system, covering pharmaceutical innovation capabilities from drug discovery, pharmaceutical research, preclinical research, clinical research to industrialization. We have three major technological systems, including prokaryotic cell technology, eukaryotic cell technology, and microecological live bacterial technology. We have successfully constructed multiple leading domestic and international technology platforms, including recombinant protein secretion and expression technology platform, recombinant protein drug industrialization technology platform, long-term recombinant protein technology platform, microecological agent research and development and industrialization technology platform, strain technology platform, antibody technology platform, and vector vaccine technology platform. The company's technology center was recognized as the "Shandong Provincial Enterprise Technology Center" in 2017, the "Jinan Protein Drug Engineering Laboratory" in 2018, and the "Guangdong Gene Engineering Recombinant Protein Drug Engineering Technology Center", the "Shandong Protein Drug Engineering Laboratory", and the "Shenzhen Postdoctoral Innovation Practice Base" in 2020. In the future, Kexing Pharmaceutical will uphold the mission of "lean pharmaceutical, lean medication, and health protection", using biotechnology to serve patients and become a leader in high-quality biopharmaceuticals. |
| Headquarter | Jinan |
| Establish Date | 8/22/1997 |
| Listed Code | 688136.SH |
| Listed Date | 12/14/2020 |
| Chairman | Deng Xueqin. |
| CEO | Zhao Yanqing. |
| Website | www.kexing.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
